METHODS FOR THE TREATMENT OF TNFα-RELATED DISEASES
Patent Information
- Application Number
- ARP20250100301
- Authority / Receiving Office
- AR · AR
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2018-02-13
- Filing Date
- 2025-02-04
- Publication Date
- 2026-07-08
Claims
The present invention relates to a method of treating a TNF-α-related disease by subcutaneous administration of an antibody that binds to TNF-α (anti-TNF-α antibody). A treatment method, composition, kit, or use according to the present invention reduces administration time and the length of hospital stays, thereby improving patient comfort and quality of life. This provides the advantage of improved patient satisfaction.
1. A pharmaceutical composition characterized in that it comprises (A) infliximab; (B) a surfactant; (C) a sugar or its derivative; and (D) a buffer comprising acetate or histidine.
17. A pharmaceutical composition according to any one of claims 1 to 16, characterized in that it comprises: (A) 90 to 145 mg / ml of an infliximab; (B) 0.02 to 0.1% (w / v) of a surfactant; (C) 1 to 10% (w / v) of a sugar or its derivative; and (D) 1 to 50 mM of a buffer comprising acetate or histidine.
24. A pre-filled syringe characterized in that it comprises the pharmaceutical composition according to any one of claims 1 to 23.
25. An autoinjector characterized in that it comprises the syringe of claim 24.